You are viewing an incomplete version of our website. Please click to reload the website as full version.

AML1-MTG8 antibody

Details for Product No. ABIN965546, Supplier: Log in to see
Immunohistochemistry (IHC)
Log in to see
Supplier Product No.
Log in to see

Showcase your results, aid the scientific community, and receive a full refund.

Contribute a validation

Learn more

Immunogen Polyclonal antibody produced in rabbits immunizing with a synthetic peptide corresponding to C-terminal residues of human AML1-MTG8(acute myelogenous leukemia 1 translocation 1 protein isoform MTG8c)
Purification Purified by antigen-specific affinity chromatography.
Background AML1-MTG8(acute myelogenous leukemia 1 translocation 1 protein isoform MTG8c) is a putative zinc finger transcription factor and oncoprotein. In acute myeloid leukemia, especially in the M2 subtype, the t(8,21)(q22,q22) translocation is one of the most frequent karyotypic abnormalities. The translocation produces a chimeric gene made up of the 5'-region of the RUNX1 gene fused to the 3'-region of this gene. The chimeric protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation. Several transcript variants encoding multiple isoforms have been found for this gene.
Application Notes ELISA, Western blotting: 1µg/ml for 2hrs.
Restrictions For Research Use only
Format Liquid
Buffer This antibody is stored in PBS, 50% glycerol
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage -20 °C
Product cited in: Martinez, Drescher, Riehle et al.: "The oncogenic fusion protein RUNX1-CBFA2T1 supports proliferation and inhibits senescence in t(8;21)-positive leukaemic cells." in: BMC cancer, Vol. 4, pp. 44, 2004 (PubMed).

Background publications Liu, Shen, Huynh et al.: "Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia." in: Cancer research, Vol. 65, Issue 4, pp. 1277-84, 2005 (PubMed).

Lindberg, Olsson, Persson et al.: "The Leukemia-associated ETO homologues are differently expressed during hematopoietic differentiation." in: Experimental hematology, Vol. 33, Issue 2, pp. 189-98, 2005 (PubMed).

Lausen, Cho, Liu et al.: "The nuclear receptor co-repressor (N-CoR) utilizes repression domains I and III for interaction and co-repression with ETO." in: The Journal of biological chemistry, Vol. 279, Issue 47, pp. 49281-8, 2004 (PubMed).

Zhang, Kalkum, Yamamura et al.: "E protein silencing by the leukemogenic AML1-ETO fusion protein." in: Science (New York, N.Y.), Vol. 305, Issue 5688, pp. 1286-9, 2004 (PubMed).

Lindberg, Olsson, Persson et al.: "Interactions between the leukaemia-associated ETO homologues of nuclear repressor proteins." in: European journal of haematology, Vol. 71, Issue 6, pp. 439-47, 2004 (PubMed).

Chevallier, Corcoran, Lennon et al.: "ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein." in: Blood, Vol. 103, Issue 4, pp. 1454-63, 2004 (PubMed).

McGhee, Bryan, Elliott et al.: "Gfi-1 attaches to the nuclear matrix, associates with ETO (MTG8) and histone deacetylase proteins, and represses transcription using a TSA-sensitive mechanism." in: Journal of cellular biochemistry, Vol. 89, Issue 5, pp. 1005-18, 2003 (PubMed).

Follows, Tagoh, Lefevre et al.: "Epigenetic consequences of AML1-ETO action at the human c-FMS locus." in: The EMBO journal, Vol. 22, Issue 11, pp. 2798-809, 2003 (PubMed).

Tonks, Pearn, Tonks et al.: "The AML1-ETO fusion gene promotes extensive self-renewal of human primary erythroid cells." in: Blood, Vol. 101, Issue 2, pp. 624-32, 2003 (PubMed).